Search

Your search keyword '"Ardavanis A"' showing total 858 results
Start Over Author "Ardavanis A"
858 results on '"Ardavanis A"'

1. Living with breast cancer: Patients’ journey within the Greek National Health System

Author

Kaitelidou Daphne, Kalogeropoulou Maria, Katostaras Theofanis, Konstantakopoulou Olympia, Minogiannis Panagiotis, Skitsou Alexandra, Siskou Olga, Charalampous Georgios, Ardavanis Alexandros, and Liaropoulos Lykourgos

Subjects
process mapping, patients’ journey, breast cancer patients, waiting times, hospital staff’s views, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Process mapping (a patient-centred method) and recording the medical, nursing and administrative staff’s views involved in the provision of care help us understand patients’ experience regarding the constraints, delays and bottlenecks of healthcare service processes and identify areas of improvement.

Published
2015
Full Text
View/download PDF

5. Exploring the Use of a Digital Platform for Cancer Patients to Report Their Demographics, Disease and Therapy Characteristics, Age, and Educational Disparities: An Early-Stage Feasibility Study

Author

Dimitra Galiti, Helena Linardou, Sofia Agelaki, Athanasios Karampeazis, Nikolaos Tsoukalas, Amanda Psyrri, Michalis Karamouzis, Konstantinos N. Syrigos, Alexandros Ardavanis, Ilias Athanasiadis, Eleni Arvanitou, Stavroula Sgourou, Anastasia Mala, Christos Vallilas, and Ioannis Boukovinas

Subjects
cancer, digital health, patients’ characteristics, age, educational disparities, socioeconomic issues, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Introduction: The increasing burden of cancer, the development of novel therapies, and the COVID-19 pandemic have made cancer care more complex. Digital innovation was then pushed toward developing platforms to facilitate access to cancer care. Age, education, and other disparities were, however, shown to limit the use of the digital health innovation. The aim of this early-stage feasibility study was to assess whether Greek cancer patients would register at CureCancer and self-report their demographics, disease and therapy characteristics, and socioeconomic issues. The study was organized by the Hellenic Society of Medical Oncology. Methods: Patients from nine cancer centers were invited to register on the CureCancer platform and complete an anonymous questionnaire on demographics, disease and therapy characteristics, and socioeconomic issues. Patients were also encouraged to upload, in a secure area for them, their medical files and share them with their physicians. They were then asked to comment on their experience of registration and how easy it was to upload their medical files. Results: Of the 159 patients enrolled, 144 (90.56%) registered, and 114 of those (79.16%) completed the questionnaire, suggesting that the study is feasible. Users’ median age was 54.5 years, and 86.8% of them were university and high school graduates. Most patients (79.8%) reported their specific type of cancer diagnosis, and all reported their therapy characteristics. Breast and lung cancers were the most common. A total of 87 patients (76.3%) reported being on active cancer therapy, 46 (40.4%) had metastatic disease, and 51 (44.7%) received supportive care medications. Eighty-one (71.05%) patients received prior cancer therapies, and twenty-seven recalled prior supportive care medications. All patients reported visiting non-oncology Health Care Professionals during the study. Nineteen of 72 (26.39%) patients who worked prior to cancer diagnosis changed work status; 49 (42.98) patients had children under 24 years; and 16 (14%) patients lived alone. Nine (7.9%) patients were members of patient associations. Registration was “much/very much” easy for 98 (86.0%) patients, while 67 (58.8%) had difficulties uploading their files. Patients commented on the well-organized data access, improved communication, feeling safe, medication adherence, interventions from a distance, and saving time and money. Over 80% of patients “preferred the digital way”. Discussion: A total of 114 patients succeeded in registering on the digital platform and reporting their demographics, disease and therapy characteristics, and socioeconomic issues. Age and educational disparities were disclosed and highlighted the need for educational programs to help older people and people of lower education use digital innovation. Health care policy measures would support patients’ financial burden associated with work changes, living alone, and children under 24 years old at school or college. Policy actions would motivate patients to increase their participation in patient associations. According to the evidence DEFINED framework, the number of patients, and the focus on enrollment, engagement, and user experience, the study fulfills actionability level criterion 1.

Published
2023
Full Text
View/download PDF

6. Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study

Author

Sykoutri Despina, Kardara Evgenia, Karagiannis Athanasios, Malliou Savvoula, Kountourakis Panteleimon, Doufexis Dimitrios, Ardavanis Alexandros, Charalampia Margari, and Rigatos Gerasimos

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Targeting angiogenesis is nowadays one of the most promising approaches for breast cancer. Bevacizumab (BEV), a VEGF-trap monoclonal antibody, was recently approved in combination with paclitaxel (PAC) for the first line treatment of advanced breast cancer (ABC). The activity of this combination in pretreated patients is not known. Methods Patients with pretreated ABC and progressive disease received BEV 10 mg/kg with PAC 135 mg/m2 every two weeks for six months and then maintenance with BEV 15 mg/kg every three weeks until progression. This regimen was chosen for better patient convenience, while maintaining the same dose intensity for both drugs. Results 42 patients were reviewed retrospectively (41 f, 1 m, mean age 57 years). Overall response rate was 35.7%. Stable disease was observed in 45.2% of patients, whereas 14.3% of patients progressed. The median overall survival was greater than 20 months, with a one year rate of 83.4%. The median progression free survival was 12.1 months, with a one year rate of 51.8%. Toxicity was in general acceptable. Conclusion This biweekly BEV/PAC combination seems to be active with acceptable toxicity in pretreated ABC with an advantage over the weekly regimen regarding quality of life and preservation of resources.

Published
2009
Full Text
View/download PDF

7. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

Author

Mountzios, Giannis, Planchard, David, Metro, Giulio, Tsiouda, Dora, Prelaj, Arsela, Lampaki, Sofia, Shalata, Walid, Riudavets, Mariona, Christopoulos, Petros, Girard, Nicolas, Albarrán-Artahona, Víctor, Garcia Campelo, Rosario, Samitas, Konstantinos, Banna, Giuseppe Luigi, Boukovinas, Ioannis, Agbarya, Abed, Koumarianou, Anna, Perdikouri, Eleni-Isidora, Kosmidis, Paris, Linardou, Helena, Mauri, David, Mavroudis, Dimitrios, Athanasiadis, Ilias, Kalofonos, Haralambos, Xenidis, Nikolaos, Korantzis, Ippokratis, Ardavanis, Alexandros, Rallis, Grigorios, Bottiglieri, Achille, Efthymiadis, Konstantinos, Oikonomopoulos, Georgios, Kokkalis, Alexandros, Saloustros, Emmanouil, Tsoukalas, Nikolaos, Bartzi, Dimitra, Economopoulou, Panagiota, Psyrri, Amanda, Reck, Martin, and Lo Russo, Giuseppe

Published
2023
Full Text
View/download PDF

9. Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group

Author

Stefania Kokkali, Emmanouil Saloustros, Dimitra Stefanou, Paris Makrantonakis, Nikolaos Kentepozidis, Ioannis Boukovinas, Nikolaos Xenidis, Panagiotis Katsaounis, Alexandros Ardavanis, Nikolaos Ziras, Athina Christopoulou, George Rigas, Kostas Kalbakis, Nikolaos Vardakis, Christos Emmanouilides, Ilias Athanasiadis, Athanassios Anagnostopoulos, Dora Hatzidaki, Efthimios Prinarakis, Foteini Simopoulou, Athanasios Kotsakis, and Vassilis Georgoulias

Subjects
metastatic breast cancer, bevacizumab, maintenance, real-life data, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical records of mBC patients, treated with front-line BEV-based chemotherapy, were retrospectively reviewed in order to generate real life safety and efficacy data. Patients with human epidermal growth factor receptor 2 (HER2)-negative mBC treated with front-line BEV in combination with chemotherapy were eligible. Maintenance therapy with BEV and/or hormonal agents was at the physicians’ discretion. Among the 387 included patients, the most common adverse events were anemia (61.9%, mainly grade 1), grade 3/4 neutropenia (16.5%), grade 1/2 fatigue (22.3%), and grade 1/2 neuropathy (19.6%). Dose reductions were required in 164 cycles (7.1%) and toxicity led to treatment discontinuation in 21 patients (5.4%). The median PFS and the median overall survival (OS) were 13.3 (95% CI: 11.7–14.8) and 32.3 months (95% CI: 27.7–36.9), respectively. Maintenance therapy, with hormonal agents (ET) and/or BEV, was associated with longer OS versus no maintenance therapy (47.2 versus 23.6 months; p < 0.001) in patients with hormone receptor (HR)-positive disease and BEV maintenance offered longer OS versus no maintenance in patients with HR-negative disease (52.8 versus 23.3; p = 0.023). These real-life data show that front-line BEV-based chemotherapy in HER2-negative mBC patients is an effective treatment with an acceptable toxicity profile. The potential benefit of maintenance treatment, especially ET, is important and warrants further research.

Published
2022
Full Text
View/download PDF

10. 113P Real-world data from patients with osteosarcoma treated in 4 medical centers in Greece: Ninety percent or greater tumor necrosis is associated with disease-free survival

Author

Moutafi, M., primary, Kyriazoglou, A., additional, Kotsantis, I., additional, Kokkali-Zervos, S., additional, Antonopoulou, P., additional, Ardavanis, G., additional, Magkou, E., additional, Georgaki, E., additional, Anastasiou, M., additional, Pantazopoulos, A., additional, Boulouta, A., additional, Kirkasiadou, M., additional, Gavrielatou, N., additional, Economopoulou, P., additional, Ardavanis, A., additional, Boukovinas, I., additional, and Psyrri, A., additional

Published
2024
Full Text
View/download PDF

11. Anatomic vs. reverse shoulder arthroplasty for the treatment of Walch B2 glenoid morphology: a systematic review and meta-analysis

Author

G. Bradley Reahl, MS, Hussein Abdul-Rassoul, MD, Ryan L. Kim, MD, Kyle S. Ardavanis, MD, David Novikov, MD, Emily J. Curry, MPH, Joseph W. Galvin, DO, Josef K. Eichinger, MD, and Xinning Li, MD

Subjects
Walch B2 glenoid, Glenohumeral osteoarthritis, Total shoulder arthroplasty, Reverse shoulder arthroplasty, Eccentric reaming, Posteriorly augmented glenoid component, Surgery, RD1-811
Abstract

Background: Walch B2 glenoid morphology with glenohumeral osteoarthritis is a difficult degenerative pattern to manage for shoulder surgeons. Anatomic total shoulder arthroplasty (TSA) in combination with eccentric reaming or bone grafting are the traditional methods of treatment. Newer approaches such as TSA with posteriorly augmented glenoid components and reverse shoulder arthroplasty (RSA) may offer better stability for the posteriorly subluxated biconcave B2 wear pattern. The aim of this systematic review is to compare mid-term surgical and functional outcomes of Walch B2 glenoids without significant rotator cuff pathology treated with TSA and RSA. Methods: The review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines by searching the MEDLINE (PubMed) and Embase (Elsevier) databases. Inclusion criteria were clinical studies that evaluated the outcomes and complications of TSA or RSA in the setting of B2 glenoid morphology without significant rotator cuff pathology. Data relevant to TSA and RSA surgical outcomes were extracted and compiled, and outcomes were compared. A meta-analysis of proportions of complication and revision rates among TSA and RSA groups was performed. Results: Overall, 16 articles were included with 414 TSAs and 78 RSAs. The average follow-up duration was 54.1 ± 14.8 months for patients undergoing TSA and 44.8 ± 10.1 months for patients undergoing RSA. The TSA group was further subdivided based on the use of eccentric reaming (135 TSAs), an augmented glenoid component (84 TSAs), or bone grafting (11 TSAs) or was unspecified (184 TSAs). Overall, patients undergoing TSA and RSA demonstrated mean improvements of 50.1 ± 8.5° and 64.7 ± 5.2° in active flexion, 58.5 ± 10.3° and 68.9 ± not reported° in active abduction, and 31.3 ± 5.7° and 29.0 ± 10.2° in active external rotation, respectively. In regard to functional outcome scores, patients undergoing TSA and RSA showed mean Constant score improvements of 38.8 ± 5.3 and 46.6 ± 3.1 points and American Shoulder and Elbow Surgeons score improvements of 48.2 ± 1.0 and 49.2 ± 25.3 points, respectively. Results of the meta-analysis with mid-term follow-up data demonstrated pooled complication rates of 9% (95% confidence interval [CI], 1%-22%) for TSA and 6% (95% CI, 0%-28%) for RSA and pooled revision rates of 2% (95% CI, 0%-8%) for TSA and 1% (95% CI, 0%-15%) for RSA. Conclusion: In the setting of Walch B2 glenoid morphology, TSA with eccentric reaming or an augmented component yields comparable outcomes to RSA. Based on the patient’s age, activity level, and expectations, both TSA and RSA can be considered a reasonable option to treat Walch B2 glenoid morphology.

Published
2021
Full Text
View/download PDF

13. Cerebral metastasis from osteosarcoma: 'Bone' in the brain

Author

Stefania Kokkali, MD, MSc, Efthymios Andriotis, MD, Elena Katsarou, MD, Angelos Theocharis, MD, Maria Drizou, MD, MSc, Elpida Magou, MD, Alexandros Tzovaras, MD, PhD, and Alexandros Ardavanis, MD, PhD

Subjects
Brain metastasis, Osteosarcoma, Calcification, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

Although brain metastases from bone and soft tissue sarcoma are uncommon, advances in sarcoma treatment have led to an increasing incidence of them. We present a 23-year-old male with a history of metastatic femoral osteosarcoma, who presented with headache and unsteady gait and was diagnosed with a cerebellar metastasis. CT scan revealed a mass in the left cerebellar parenchyma with large intralesional central calcification and perilesional edema. Corticosteroid treatment led to neurological symptoms resolution, with a rapid tapering. The patient had also lung metastases and we opted to administer systemic treatment with the tyrosine kinase inhibitor cabozantinib. Given the relative radioresistance of osteosarcomas, the patient did not receive radiation therapy.

Published
2020
Full Text
View/download PDF

14. ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer

Author

Koumarianou, A., Makrantonakis, P., Zagouri, F., Papadimitriou, C., Christopoulou, A., Samantas, E., Christodoulou, C., Psyrri, A., Bafaloukos, D., Aravantinos, G., Papakotoulas, P., Baka, S., Andreadis, C., Alexopoulos, A., Bompolaki, I., Kampoli, Κ., Liori, S., Karvounis, K., and Ardavanis, A.

Published
2020
Full Text
View/download PDF

15. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

Author

Brown, II, Tommy A., Mittendorf, Elizabeth A., Hale, Diane F., Myers, III, John W., Peace, Kaitlin M., Jackson, Doreen O., Greene, Julia M., Vreeland, Timothy J., Clifton, G. Travis, Ardavanis, Alexandros, Litton, Jennifer K., Shumway, Nathan M., Symanowski, J., Murray, James L., Ponniah, Sathibalan, Anastasopoulou, E. A., Pistamaltzian, N. F., Baxevanis, Constantin N., Perez, Sonia A., Papamichail, Michael, and Peoples, George E.

Published
2020
Full Text
View/download PDF

16. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

Author

Souglakos, J., Boukovinas, I., Kakolyris, S., Xynogalos, S., Ziras, N., Athanasiadis, A., Androulakis, N., Christopoulou, A., Vaslamatzis, M., Ardavanis, A., Emmanouilides, C., Bompolaki, I., Kourousis, C., Makrantonakis, P., Christofyllakis, C., Athanasiadis, E., Kentepozidis, N., Karampeazis, A., Katopodi, U., Anagnosopoulos, A., Papadopoulos, G., Prinarakis, E., Kalisperi, A., Mavroudis, D., and Georgoulias, V.

Published
2019
Full Text
View/download PDF

18. MA01.03 Thromboprophylaxis for Lung Cancer Patients: Combined Results from GMaT and ACT4CAT Studies

Author

Tsoukalas, N.G., primary, Christopoulou, A., additional, Timotheadou, E., additional, Koumarianou, A., additional, Ardavanis, A., additional, Athanasiadis, I., additional, Demiri, S., additional, Bokas, A., additional, Samelis, G., additional, Peroukidis, S., additional, Papatsimpas, G., additional, Andreadis, C., additional, Nikolakopoulos, A., additional, Psyrri, A., additional, Kapodistrias, N., additional, Papakostas, P., additional, Aravantinos, G., additional, Athanasiadis, A., additional, Papakotoulas, P., additional, and Boukovinas, I., additional

Published
2023
Full Text
View/download PDF

22. 2107P Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients

Author

Tsoukalas, N.G., primary, Christopoulou, A.N., additional, Timotheadou, E., additional, Koumarianou, A., additional, Ardavanis, A., additional, Athanasiadis, I., additional, Demiri, M., additional, Bokas, A., additional, Samelis, G.F., additional, Peroukidis, S., additional, Papatsimpas, G., additional, Andreadis, C., additional, Kalofonos, C., additional, Psyrri, A., additional, Kapodistrias, N., additional, Papakostas, P., additional, Pentheroudakis, G., additional, Aravantinos, G., additional, Papakotoulas, P., additional, and Boukovinas, I., additional

Published
2023
Full Text
View/download PDF

24. Exploring the Use of a Digital Platform for Cancer Patients to Report Their Demographics, Disease and Therapy Characteristics, Age, and Educational Disparities: An Early-Stage Feasibility Study

Author

Galiti, Dimitra, primary, Linardou, Helena, additional, Agelaki, Sofia, additional, Karampeazis, Athanasios, additional, Tsoukalas, Nikolaos, additional, Psyrri, Amanda, additional, Karamouzis, Michalis, additional, Syrigos, Konstantinos N., additional, Ardavanis, Alexandros, additional, Athanasiadis, Ilias, additional, Arvanitou, Eleni, additional, Sgourou, Stavroula, additional, Mala, Anastasia, additional, Vallilas, Christos, additional, and Boukovinas, Ioannis, additional

Published
2023
Full Text
View/download PDF

25. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Author

Koroveshi, Dhurata, Bouzid, Kamel, Casalnuovo, Monica, Cascallar, Diana, Korbenfeld, Ernesto Pablo, Bastick, Patricia, Beith, Jane, Colosimo, Maree, Friedlander, Michael, Ganju, Vinod, Green, Michael, Patterson, Kevin, Redfern, Andrew, Richardson, Gary, Ceric, Timur, Gordana, Kecman, Beato, Carlos Augusto, Ferrari, Marcela, Hegg, Roberto, Helena, Vanessa, Ismael, Gustavo Fernando, Lessa, Alvaro Edson, Mano, Max, Morelle, Alessandra, Nogueira, Jose Alberto, Timcheva, Konstanta, Tomova, Antoaneta, Tsakova, Maya, Zlatareva-Petrova, Ani, Asselah, Jamil, Assi, Hazem, Brezden-Masley, Christine, Chia, Stephen, Freedman, Ori, Harb, Mohammed, Joy, Anil Abraham, Kulkarni, Swati, Prady, Catherine, Gaete, Alejandro Andres Acevedo, Matamala, Luis, Torres, Roberto, Yanez, Eduardo, Franco, Sandra, Urrego, Marcela, Gugić, Damir, Vrbanec, Damir, Melichar, Bohuslav, Prausová, Jana, Vyzula, Rostislav, Pilarte, Rafael Gutierrez, León, María Isabel, Muñoz, Rene, Ramos, Glenda, Azeem, Hamdy Abdel, Aziz, Amr Abdel, El Zawahry, Heba, Osegueda, Finlander Rosales, Alexandre, Jerome, Artignan, Xavier, Barletta, Hugues, Beguier, Emmanuel, Berdah, Jean-François, Marty, Chantal Bernard, Bollet, Marc, Bourgeois, Hugues, Bressac, Claude, Burki, Franck, Campone, Mario, Coeffic, David, Cojocarasu, Oana Zveltlana, Dagada, Corinne, Dalenc, Florence, Del Piano, Francesco, Desauw, Christophe, Desmoulins, Isabelle, Dohollou, Nadine, Egreteau, Joelle, Ferrero, Jean-Marc, Foa, Cyril, Garidi, Reda, Gasnault, Laurent, Gligorov, Joseph, Guardiola, Emmanuel, Hamizi, Salima, Jarcau, Rosana, Jacquin, Jean-Philippe, Jaubert, Dominique, Jolimoy, Geneviève, Mineur, Hortense Laharie, Largillier, Remy, Leduc, Bernard, Martin, Philippe, Melis, Adrien, Monge, Jeremy, Moullet, Isabelle, Mousseau, Mireille, Nguyen, Suzanne, Orfeuvre, Hubert, Petit, Thierry, Pivot, Xavier, Priou, Frank, Bach, Isabelle Sillet, Simon, Helene, Stefani, Laetitia, Uwer, Lionel, Youssef, Ali, Aktas, Bahriye, von der Assen, Albert, Augustin, Doris, Balser, Christina, Bauer, Lelia-Eveline, Bechtner, Christina, Beyer, Greta, Brucker, Cosima, Bückner, Ute, Busch, Steffi, Christensen, Bernd, Deryal, Mustafa, Farrokh, Andre, Faust, Elke, Friedrichs, Kay, Graf, Heiko, Griesshammer, Martin, Grischke, Eva-Maria, Hänle, Claudia, Heider, Andrea, Henschen, Stephan, Hesse, Tobias, Jackisch, Christian, Kisro, Jens, Köhler, Andreas, Kuemmel, Sherko, Lampe, Dieter, Lantzsch, Tilmann, Latos, Kunibert, Lex, Benno, Liedtke, Cornelia, Luedders, Doerte, Maintz, Christoph, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-won, Paul, Marion, Prechtl, Anita, Ringsdorf, Uta, Runnebaum, Ingo, Ruth, Sylvia, Salat, Christoph, Scheffen, Iris, Schilling, Jörg, Schmatloch, Sabine, Schmidt, Marcus, Schneeweiss, Andreas, Schrader, Iris, Seipelt, Gernot, Simon, Elke, Stefek, Andrea, Stickeler, Elmar, Thill, Marc, Tio, Joke, Tuczek, Anna, Warm, Mathias, Weigel, Michael, Wischnik, Arthur, Wojcinski, Sebastian, Ziegler-Löhr, Katja, Aravantinos, Gerasimos, Ardavanis, Alexandros, Fountzilas, George, Gogas, Helen, Kakolyris, Stylianos, Mavroudis, Dimitris, Papadimitriou, Christos, Papandreou, Christos, Papazisis, Konstantinos, Castro, Hugo, Hernandez-Monroy, Cesar Estuardo, Ngan, Roger, Yeo, Winnie, Bittner, Nora, Boer, Katalin, Csejtei, Andras, Horvath, Zsolt, Kocsis, Judit, Mangel, László Csaba, Mezei, Klara, Nagy, Zsuzsanna, Szanto, Janos, Atmakusuma, Djumhana, Fadjari, Heri, Kurnianda, Djohan, Prayogo, Nugroho, Tanggo, Eddie Herman, Coate, Linda, Hennessy, Bryan, Kelly, Cathy, Martin, Michael, Nasim, Saira, O'Connor, Miriam, Aieta, Michele, Allegrini, Giacomo, Amadori, Dino, Bidoli, Paolo, Biti, Giampaolo, Bordonaro, Roberto, Bottini, Alberto, Carterni, Giacomo, Cavanna, Luigi, Cazzaniga, Marina, Cognetti, Francesco, Contu, Antonio, Cruciani, Giorgio, Donadio, Michela, Falcone, Alfredo, Farci, Daniele, Forcignanò, R. Chiara, Frassoldati, Antonio, Gaion, Fernando, Gamucci, Teresa, Giotta, Francesco, de Laurentiis, Michele, Livi, Lorenzo, Lorusso, Vito, Maiello, Evaristo, Marchetti, Paolo, Mariani, Gabriella, Mion, Marta, Moscetti, Luca, Musolino, Antonino, Pazzola, Antonio, Pedrazzoli, Paolo, Pigi, Andrea, de Placido, Sabino, Caremoli, Elena Rota, Santoro, Armando, Tienghi, Amelia, Ahn, Jin-Seok, Jung, Kyung Hae, Lee, Keun Seok, Lee, Soo Hyeon, Seo, Jae Hong, Sohn, Joo-Hyuk, Cesas, Alvydas, Juozaityte, Elona, Cheah, Nellie Lay Chin, Chong, Flora Li Tze, Devi, Beena C.R., Phua, Vincent, Teoh, Darren, Ching, Lee Wei, Yusof, Mastura, Corona, Jorge, Dominguez, Adriana, Mendoza, René Lazaro González, Hernandez, Carlos Alberto, Ramiro, Alejandro Juarez, Santos, Juan Matos, Espinosa, Paola Morales, Villarreal Garza, Cynthia Mayte, Errihani, Hassan, Bakker, Sandra, van den Berkmortel, Franchette, Blaisse, R.J.B., Huinink, Daan ten Bokkel, van den Bosch, J., Braun, J.J., Dercksen, M.W., Droogendijk, Helga, Erdkamp, Frans, Haringhuizen, Annebeth, de Jongh, F.E., Kok, T.C., Los, Maartje, Madretsma, Stanley, Terwogt, Jetske M. Meerum, van der Padt, Annemieke, van Rossum-Schornagel, Quirine Clementine, Smilde, T.J., de Valk, Bart, van der Velden, Annette, van Warmerdam, Laurence, van de Wouw, A.J., North, Richard, Kersten, Christian, Mjaaland, Ingvild, Wist, Erik, Aziz, Zeba, Masood, Nehal, Rashid, Kamran, Shah, Mazhar, Alcedo, Juan Carlos, Aleman, Diana, Neciosup, Silvia, Reategui, Rocio, Valdiviezo, Natalia, Vera, Luis, Fernando, Gracieux, Roque, Fernando, Strebel, Heinrik Martin, Krzemieniecki, Krzysztof, Litwiniuk, Maria, Mruk, Andrzej, Pienkowski, Tadeusz, Sawrycki, Piotr, Slomian, Grzegorz, Tomczak, Piotr, Afonso, Noemia, Cardoso, Fátima, Damasceno, Margarida, Nave, Monica, Badulescu, Florinel, Ciule, Larisa, Curescu, Stefan, Eniu, Alexandru, Filip, Dumitru, Grecea, Daniela, Jinga, Dan-Corneliu, Lungulescu, Dan, Oprean, Cristina Marinela, Stanculeanu, Dana Lucia, Turdean, Maria, Dvornichenko, Viktoria, Emelyanov, Sergey, Lichinitser, Mikhail, Manikhas, Alexey, Sakaeva, Dina, Shirinkin, Vadim, Stroyakovskiy, Daniil, Abulkhair, Omalkhair, Zekri, Jamal, Filipovic, Sladjana, Kovcin, Vladimir, Nedovic, Jasmina, Pesic, Jasna, Vasovic, Suzana, Ng, Raymond, Bystricky, Branislav, Leskova, Jaroslava, Mardiak, Jozef, Mišurová, Etela, Wagnerova, Maria, Takač, Iztok, Demetriou, Georgia Savva, Dreosti, Lydia, Govender, Poovandren, Jordaan, Johannes Petrus, Veersamy, Petrosian, Romero, Jose Luis Alonso, Lopez, Norberto Batista, Arias, Carmen Cañabate, Chacon, Jose, Aramburo, Antonio Fernandez, Morales, Luis Antonio Fernandez, Garcia, Mirta, Estevez, Laura Garcia, Garcia-Palomo Perez, Andres, Garcia Saenz, Jose Angel, Garcia Sanchis, Laura, Cubells, Laia Garrigos, Cortijo, Lucia Gonzalez, Santiago, Santiago Gonzalez, De Aranguiz, Blanca Hernando Fernandez, Mañas, José Juan Illarramendi, Gallego, Pedro Jimenez, Cussac, Antonio Llombart, Ferrandiz, Cristina Llorca, Garrido, Maria Lomas, Alvarez, Pilar Lopez, Vega, Jose Manuel Lopez, Del Prado, Purificacion Martinez, Jañez, Noelia Martinez, Murillo, Serafin Morales, Rosales, Adolfo Murias, Jaso, Laura Murillo, Fernandez, Ignacio Pelaez, Martorell, Antonia Perello, Carrion, Ramon Perez, Simon, Sonia Pernas, Alcibar, Arrate Plazaola, Lorenzo, Jose Ponce, Garcia, Vanesa Quiroga, Asensio, Teresa Ramon y Cajal, Maicas, Maria Dolores Torregrosa, Villanueva Silva, Maria Jose, Killander, Fredrika, Svensson, Jan Henry, Fehr, Mathias, Hauser, Nik, Müller, Andreas, Pagani, Olivia, Passmann-Kegel, Heike, Popescu, Razvan, Rabaglio, Manuela, Rauch, Daniel, Schlatter, Christina, Zaman, Khalil, Chang, Tsai-Wang, Huang, Chiun-Sheng, Wang, Hwei-Chung, Yu, Jyh-Cherng, Bandidwattanawong, Chanyoot, Maneechavakajorn, Jedzada, Seetalarom, Kasan, Dejthevaporn, Thitiya (Sirisinha), Somwangprasert, Areewan, Vongsaisuwon, Mawin, Akbulut, Hakan, Altundag, Kadri, Arican, Ali, Bozcuk, Hakan, Eralp, Yesim, Idris, Mohamed, Isikdogan, Abdurrahman, Senol, Coskun Hasan, Sevinc, Alper, Uygun, Kazim, Yucel, Eftal, Yucel, Idris, Yumuk, Fulden, Shparyk, Yaroslav, Voitko, Nataliia, Jaloudi, Mohammed, Adams, Jocelyn, Agrawal, Rajiv, Ahmed, Samreen, Alhasso, Abdulla, Allerton, Rozenn, Anwar, Suhail, Archer, Caroline, Ashford, Richard, Barraclough, Lisa, Bertelli, Gianfilippo, Bishop, Jill, Branson, Tony, Butt, Mohammed, Chakrabarti, Amit, Chakraborti, Prabir, Churn, Mark, Crowley, Clare, Davis, Ruth, Dhadda, Amandeep, Eldeeb, Hany, Fraser, Judith, Hall, Julia, Hickish, Tamas, Hogg, Martin, Howe, Theresa, Joffe, Jonathan, Kelleher, Muireann, Kelly, Stephen, Kendall, Anne, Kristeleit, Hartmut, Lumsden, Graeme, Macmillan, Craig, MacPherson, Iain, Malik, Zafar, Mithal, Natasha, Neal, Anthony, Panwar, Udaiveer, Proctor, Andrew, Proctor, Steven John, Raj, Sanjay, Rehman, Shazza, Sandri, Ines, Scatchard, Kate, Sherwin, Elizabeth, Sims, Eliot, Singer, Julian, Smith, Sarah, Tahir, Saad, Taylor, Wendy, Tsalic, Medy, Verrill, Mark, Wardley, Andrew, Waters, Simon, Wheatley, Duncan, Wright, Kathryn, Yuille, Frances, Alonso, Isabel, Artagaveytia, Nora, Rodriguez, Robinson, Arbona, Esther, Garcia, Yuraima, Lion, Lorena, Marcano, Dalila, Van Thuan, Tran, Gligorov, J., Ataseven, B., Verrill, M., De Laurentiis, M., Jung, K.H., Azim, H.A., Al-Sakaff, N., Lauer, S., Shing, M., and Pivot, X.

Published
2017
Full Text
View/download PDF

32. Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 'MELPOMENI' study)

Author

Athanasios, Alexopoulos, Charisios, Karanikiotis, Alexandros, Ardavanis, Ioannis, Boukovinas, Parisios, Makrantonakis, Christos, Papadimitriou, Athanasios, Athanasiadis, Anastasios, Boutis, Stylianos, Giassas, Stylianos, Kakolyris, Georgios, Koumakis, Konstantinos, Papazisis, Adamantia, Psyrri, Nikolaos, Ziras, Sofia, Baka, Nikolaos, Kentepozidis, and Vasiliki, Michalaki

Subjects
Aged, 80 and over, Cancer Research, Drug-Related Side Effects and Adverse Reactions, Greece, Receptor, ErbB-2, Breast Neoplasms, General Medicine, Middle Aged, Survival Analysis, Drug Administration Schedule, Postmenopause, Treatment Outcome, Receptors, Estrogen, Oncology, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Humans, Female, Everolimus, Neoplasm Metastasis, Neoplasm Recurrence, Local, Receptors, Progesterone, Aged
Abstract

This study aimed to provide real-world safety and effectiveness data of everolimus (EVE) plus exemestane (EXE) in estrogen receptor positive/human epidermal growth factor receptor 2 negative (ERThis prospective observational study was conducted by 19 hospital-based oncologists in Greece. Eligible patients were treated with EVE+EXE in the first-line setting; EVE was initiated according to the approved label.Overall, 75 eligible patients (mean age: 66.9 years; visceral metastases: 49.3%; bone-only metastases: 37.3%) were included in the effectiveness analyses. Over a median (interquartile range) of 12.1 months (range=4.2-20.5 months) of EVE treatment, the median progression-free survival was 18.0 months and the overall response rate was 22.7%. Among patients that received ≥1 EVE dose (n=80), the incidence of EVE-related adverse events was 72.5% (serious: 55.0%); stomatitis (22.5%), fatigue (22.5%), pneumonitis (18.8%); and cough (18.8%) were the most common.In the routine care in Greece, EVE demonstrates clinical benefit and a predictable safety profile.

Published
2022
Full Text
View/download PDF

34. Association between Intratumoral CD8+ T Cells with FoxP3+ and CD163+ Cells: A Potential Immune Intrinsic Negative Feedback Mechanism for Acquired Immune Resistance

Author

Sotirios P. Fortis, Michael Sofopoulos, Maria Goulielmaki, Niki Arnogiannaki, Alexandros Ardavanis, Sonia A. Perez, Angelos D. Gritzapis, and Constantin N. Baxevanis

Subjects
Cancer Research, Oncology, tumor microenvironment, acquired immune resistance, CD8+ T cells, FoxP3+ cells, CD163+ cells, breast cancer
Abstract

Acquired immune resistance (AIR) describes a situation in which cancer patients who initially responded clinically to immunotherapies, after a certain period of time, progress with their disease. Considering that AIR represents a feedback response of the tumor against the immune attack generated during the course of immunotherapies, it is conceivable that AIR may also occur before treatment initiation as a mechanism to escape endogenous adaptive antitumor immunity (EAAI). In the present study, we assessed the EAAI in paraffin-embedded breast primary tumor tissue samples and drew correlations with the clinical outcomes. In particular, we analyzed densities of CD8+ cells as elements mediating antitumor cytotoxicity, and of CD163+ and FoxP3+ cells as suppressor elements. We found a direct correlation between the densities of CD8+ cells and of CD163+ and/or FoxP3+ cells in the vast majority of patients’ tumors. Importantly, the vast majority of patients whose tumors were overpopulated by CD8+ cells developed AIR, which was characterized by high intratumoral CD163+ and/or FoxP3+ cell densities and reduced overall survival (OS). We also showed that AIR depends on the levels of CD8+ cell-ratios in the tumor center to the invasive margin. Our data suggest that tumors develop AIR only when under a robust endogenous immune pressure.

Published
2022
Full Text
View/download PDF

38. Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)

Author

Matikas, A., Kentepozidis, Ν., Ardavanis, A., Vaslamatzis, M., Polyzos, A., Emmanouilides, Ch., Katsaounis, P., Koinis, F., Xynogalos, S., Christopoulou, A., Ziras, N., Tegos, Th., Prinarakis, E., Hatzidaki, D., Georgoulias, V., Kotsakis, A., and on behalf of the HORG’s Lung Cancer Working Group

Published
2016
Full Text
View/download PDF

39. 1585P Thromboprophylaxis “challenge” in oncology patients with high burden for thrombosis: Real-world data from GMaT and ACT4CAT studies

Author

Tsoukalas, N.G., primary, Christopoulou, A.N., additional, Timotheadou, E., additional, Koumarianou, A., additional, Ardavanis, A., additional, Athanasiadis, I., additional, Demiri, M., additional, Bokas, A., additional, Samelis, G.F., additional, Peroukidis, S., additional, Papatsimpas, G., additional, Andreadis, C., additional, Nikolakopoulos, A., additional, Psyrri, A., additional, Kapodistrias, N., additional, Papakostas, P., additional, Aravantinos, G., additional, Athanasiadis, A., additional, Papakotoulas, P., additional, and Boukovinas, I., additional

Published
2022
Full Text
View/download PDF

40. EP10.01-018 Thromboprophylaxis for Lung Cancer Patients: Results From ACT4CAT Trial

Author

Tsoukalas, N., primary, Christopoulou, A., additional, Timotheadou, E., additional, Athanasiadis, I., additional, Koumarianou, A., additional, Peroukidis, S., additional, Samelis, G., additional, Psyrri, A., additional, Kapodistrias, N., additional, Nikolakopoulos, A., additional, Andreadis, C., additional, Ardavanis, A., additional, Kalofonos, C., additional, Samantas, E., additional, Papandreou, C., additional, Mavroudis, D., additional, Bokas, A., additional, Barbounis, V., additional, Kentepozidis, N., additional, Athanasiadis, A., additional, Papakotoulas, P., additional, and Boukovinas, I., additional

Published
2022
Full Text
View/download PDF

41. Breakthrough Cancer Pain: An Observational Study of 1000 European Oncology Patients

Author

Davies, Andrew, Buchanan, Alison, Zeppetella, Giovambattista, Porta-Sales, Josep, Likar, Rudolf, Weismayr, Wolfgang, Slama, Ondrej, Korhonen, Tarja, Filbet, Marilene, Poulain, Philippe, Mystakidou, Kyriaki, Ardavanis, Alexandros, O’Brien, Tony, Wilkinson, Pauline, Caraceni, Augusto, Zucco, Furio, Zuurmond, Wouter, Andersen, Steen, Damkier, Anette, Vejlgaard, Tove, Nauck, Friedemann, Radbruch, Lukas, Sjolund, Karl-Fredrik, and Stenberg, Mariann

Published
2013
Full Text
View/download PDF

46. Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients

Author

Balalis, Dimitrios, primary, Tsakogiannis, Dimitrios, additional, Kalogera, Eleni, additional, Kokkali, Stefania, additional, Tripodaki, Elli, additional, Ardavanis, Alexandros, additional, Manatakis, Dimitrios, additional, Dimas, Dionysios, additional, Koufopoulos, Nektarios, additional, Fostira, Florentia, additional, Korkolis, Dimitrios, additional, Misitzis, Ioannis, additional, Vassos, Nikolaos, additional, Spiliopoulou, Chara, additional, Vlachodimitropoulos, Dimitrios, additional, Bletsa, Garyfalia, additional, and Arkadopoulos, Nikolaos, additional

Published
2022
Full Text
View/download PDF

47. Prevention of venous thromboembolism in ambulatory patients with active cancer: Results from ACT4CAT study.

Author

Tsoukalas, Nikolaos, primary, Christopoulou, Athina, additional, Koumarianou, Anna, additional, Timotheadou, Eleni, additional, Athanasiadis, Ilias, additional, Samelis, Georgios, additional, Peroukidis, Stavros, additional, Psyrri, Amanda, additional, Kapodistrias, Nikolaos, additional, Nikolakopoulos, Achilleas, additional, Demiri, Stamatina G, additional, Andreadis, Charalampos, additional, Bokas, Alexandros, additional, Ardavanis, Alexandros, additional, Samantas, Epaminondas, additional, Mavroudis, Dimitrios, additional, Barbounis, Vasileios, additional, Athanasiadis, Athanasios, additional, Papakotoulas, Pavlos, additional, and Boukovinas, Ioannis, additional

Published
2022
Full Text
View/download PDF

48. PO-45: Cancer-associated thrombosis (CAT) in gynecological cancers: data from ACT4CAT study

Author

Tsoukalas, N., primary, Christopoulou, A., additional, Timotheadou, E., additional, Athanasiadis, I., additional, Koumarianou, A., additional, Peroukidis, S., additional, Samelis, G., additional, Psyrri, A., additional, Kapodistrias, N., additional, Nikolakopoulos, A., additional, Andreadis, C., additional, Ardavanis, A., additional, Samantas, E., additional, Papandreou, C., additional, Mavroudis, D., additional, Bokas, A., additional, Barbounis, V., additional, Kentepozidis, N., additional, Athanasiadis, A., additional, Papakotoulas, P., additional, and Boukovinas, I., additional

Published
2022
Full Text
View/download PDF

49. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

Author

Sathibalan Ponniah, Tommy A. Brown, Diane F. Hale, Constantin N. Baxevanis, N. F. Pistamaltzian, John W. Myers, Kaitlin M. Peace, Eleftheria A. Anastasopoulou, Doreen O. Jackson, Jennifer K. Litton, James L. Murray, Michael Papamichail, Nathan M. Shumway, James T. Symanowski, George E. Peoples, Alexandros Ardavanis, Elizabeth A. Mittendorf, Sonia A. Perez, Timothy J. Vreeland, Julia M. Greene, and G. Travis Clifton

Subjects
0301 basic medicine, Oncology, Cancer Research, Receptor, ErbB-2, medicine.medical_treatment, Disease, law.invention, 0302 clinical medicine, Breast cancer, Randomized controlled trial, law, Single-Blind Method, Prospective Studies, skin and connective tissue diseases, Carcinoma, Ductal, Breast, Middle Aged, Prognosis, Clinical Trial, Gene Expression Regulation, Neoplastic, Survival Rate, Receptors, Estrogen, 030220 oncology & carcinogenesis, Vaccines, Subunit, Female, Immunotherapy, Receptors, Progesterone, Adult, medicine.medical_specialty, Subgroup analysis, Breast Neoplasms, 03 medical and health sciences, Internal medicine, HER2, medicine, Biomarkers, Tumor, Humans, In patient, Neoplasm Invasiveness, AE37, business.industry, GP2, Significant difference, medicine.disease, Peptide Fragments, Carcinoma, Lobular, 030104 developmental biology, Landmark analysis, Neoplasm Recurrence, Local, business, Vaccine, Follow-Up Studies
Abstract

Purpose AE37 and GP2 are HER2 derived peptide vaccines. AE37 primarily elicits a CD4+ response while GP2 elicits a CD8+ response against the HER2 antigen. These peptides were tested in a large randomized trial to assess their ability to prevent recurrence in HER2 expressing breast cancer patients. The primary analyses found no difference in 5-year overall disease-free survival (DFS) but possible benefit in subgroups. Here, we present the final landmark analysis. Methods In this 4-arm, prospective, randomized, single-blinded, multi-center phase II trial, disease-free node positive and high-risk node negative breast cancer patients enrolled after standard of care therapy. Six monthly inoculations of vaccine (VG) vs. control (CG) were given as the primary vaccine series with 4 boosters at 6-month intervals. Demographic, safety, immunologic, and DFS data were evaluated. Results 456 patients were enrolled; 154 patients in the VG and 147 in CG for AE37, 89 patients in the VG and 91 in CG for GP2. The AE37 arm had no difference in DFS as compared to CG, but pre-specified exploratory subgroup analyses showed a trend towards benefit in advanced stage (p = 0.132, HR 0.573 CI 0.275–1.193), HER2 under-expression (p = 0.181, HR 0.756 CI 0.499–1.145), and triple-negative breast cancer (p = 0.266, HR 0.443 CI 0.114–1.717). In patients with both HER2 under-expression and advanced stage, there was significant benefit in the VG (p = 0.039, HR 0.375 CI 0.142–0.988) as compared to CG. The GP2 arm had no significant difference in DFS as compared to CG, but on subgroup analysis, HER2 positive patients had no recurrences with a trend toward improved DFS (p = 0.052) in VG as compared to CG. Conclusions This phase II trial reveals that AE37 and GP2 are safe and possibly associated with improved clinical outcomes of DFS in certain subgroups of breast cancer patients. With these findings, further evaluations are warranted of AE37 and GP2 vaccines given in combination and/or separately for specific subsets of breast cancer patients based on their disease biology.

Published
2020

50. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone‐targeting agents

Author

Helena Linardou, Michalis V. Karamouzis, Dimitrios Tzanninis, Maria Kouri, Carla Ripamonti, Cesar A. Migliorati, Ourania Nicolatou-Galitis, Adamantia Nikolaidi, Stavroula Droufakou, Konstantina‐Eleni Alexiou, Evangelia Razis, Styllianos Giassas, Marie-Christine Kyrtsonis, Evangelos Galitis, Ilias Athanasiadis, Dimitra Galiti, Amanda Psyrri, Sotirios Sachanas, Apostolos Laskarakis, Konstantinos Laschos, Fotini Antoniou, Emmanouil Vardas, George Rigakos, Anna Ntokou, Alexandros Ardavanis, Erofili Papadopoulou, Kostas Tsiklakis, and Danai Daliani

Subjects
medicine.medical_specialty, Necrosis, Fistula, medicine.medical_treatment, Asymptomatic, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, medicine, Humans, General Dentistry, Dental alveolus, Bone Density Conservation Agents, Diphosphonates, business.industry, Cancer, Histology, 030206 dentistry, medicine.disease, Surgery, Otorhinolaryngology, Dental extraction, 030220 oncology & carcinogenesis, Tooth Extraction, Bisphosphonate-Associated Osteonecrosis of the Jaw, medicine.symptom, Osteonecrosis of the jaw, business
Abstract

We reported the alveolar bone histology prior to dental extractions in cancer patients, who received bone-targeting agents (BTA).Fifty-four patients were included. Patients underwent extractions, and bone biopsies were taken.Extractions were performed due to pain, swelling, purulence, fistula, and numbness, not responding to treatment, in 40 patients (group A); extractions due to asymptomatic, non-restorable teeth, were performed in 14 patients (group B). Complete alveolar jaw bone histological necrosis was observed in 28 of 40 (70%) patients of group A and none of group B (p .001). The development of clinical osteonecrosis (MRON) was assessed in 44 patients; 10 patients, who were also treated with Low Level Laser Treatments-LLLT, were excluded from this analysis, as the alternative therapies were a confounding factor. Twelve patients, with alveolar bone histological necrosis prior to extraction, developed medication-related osteonecrosis of the jaw (MRONJ) compared with two patients with vital or mixed vital/non-vital bone (p .0007). BTAs1 year and concurrent targeted therapy were also significantly associated with MRONJ (p = .016 and p = .050).Pain, swelling, purulence, fistula, and numbness were significantly associated with complete bone histological necrosis prior to extractions and increased MRONJ development. Research is justified to explore whether histological necrosis represents an early stage of osteonecrosis.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results